HealthDay News — For young patients with primary multimetastatic Ewing sarcoma, pazopanib is well-tolerated and effective, according to a study published online Oct. 22 in Frontiers in Oncology.

Ewing sarcoma is one of the most common bone cancers seen in children, and if it spreads, it can be deadly. One study found that under a quarter of children with multi-metastatic Ewing sarcoma ...

The drug pazopanib (Votrient) extended the lives of a small group of kids with Ewing sarcoma, which causes cancerous tumors ...

Ewing sarcoma is a malignant type of bone tumor, meaning it is a form of cancer that spreads. According to a 2024 review, Ewing sarcoma is the second most common primary cancerous bone tumor. It ...

Certain medical conditions begin with abnormal cell growth in bones or soft tissues, affecting both children and adults. These conditions often arise without a clear cause, driven by random genetic ...

Ewing sarcoma develops due to genetic causes that include changes to a person’s DNA and chromosomes. It more often affects teenagers and young adults, males, and white people. The exact cause of Ewing ...

Shanghai Pharmaceuticals Holding Co Class H (($SHPMF)) announced an update on their ongoing clinical study. Shanghai Pharmaceuticals Holding Co.

Ewing sarcoma is a rare and serious diagnosis, largely impacting children. The disease only accounts for about 1% of all pediatric cancers in the U.S., with about 250 children diagnosed every year, ...

Survival rates from small trial suggest that adding pazopanib to standard treatment for Ewing sarcoma in children may extend lives without adding severe toxicity.

Treatment depends on the sarcoma’s type, location, grade, and stage, as well as the patient’s overall health and goals of care. Many patients benefit from a team approach that includes oncologists, ...

Kim Fellner enters the waiting area at Sibley Memorial Hospital to receive her third course of radiation treatment for Ewing’s sarcoma. (Candace Dane Chambers/For The Washington Post) Guest column by ...